Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Sep 21, 2009; 15(35): 4392-4401
Published online Sep 21, 2009. doi: 10.3748/wjg.15.4392
Published online Sep 21, 2009. doi: 10.3748/wjg.15.4392
Table 1 Effect of p38 inhibitors SB203580 and SB202190 on lansoprazole-induced HO-1 promoter activity in NIH3T3-HO-1-luc cells (mean ± SD, %)
| Treatment | HO-1 promoter activity |
| Lansoprazole (30 μmol/L) | 100.0 ± 8.4 |
| Lansoprazole (30 μmol/L) + SB203580 (10 μmol/L) | 109.2 ± 9.0 |
| Lansoprazole (30 μmol/L) + SB203580 (20 μmol/L) | 108.8 ± 12.6 |
| Lansoprazole (30 μmol/L) + SB203580 (30 μmol/L) | 101.8 ± 14.4 |
| Lansoprazole (30 μmol/L) + SB202190 (0.1 μmol/L) | 91.0 ± 3.7 |
| Lansoprazole (30 μmol/L) + SB202190 (1.0 μmol/L) | 112.4 ± 15.1 |
- Citation: Schulz-Geske S, Erdmann K, Wong RJ, Stevenson DK, Schröder H, Grosser N. Molecular mechanism and functional consequences of lansoprazole-mediated heme oxygenase-1 induction. World J Gastroenterol 2009; 15(35): 4392-4401
- URL: https://www.wjgnet.com/1007-9327/full/v15/i35/4392.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.4392